Skip to main content




Dec 01, 2022

A UK study suggests the equivalent outcomes when patients with interstitial lung disease (ILD) associated with connective tissue disease (CTD) are treated with either intravenous rituximab (RTX) or cyclophosphamide (CTX), but with fewer adverse events with RTX. 

Read Article
Lungs breathing

RA-ILD takes centre stage

Interstitial lung disease is common in RA, occurring in approximately 8% of RA patients. It is associated with a poor prognosis, and a median survival of 3 years. This important condition has often been neglected within the spectrum of RA research. That is changing, with excellent research

Read Article
Meng et al. ESR/CRP and steroid associated increased risk of MACE in IA. NSAIDs/COX-2 and MTX associated reduced risk of MACE in IA. @RheumNow #ACR22 Abstr#1207
Ab1486 #ACR22 @Keith_Colaco: Disease-specific CV Risk Prediction Model for PsO, PsA Prediction base model w only traditional CV risks excellent (AUC 85.5) Expanded model w damaged jts did not improve risk discrimination @Rheumnow
Multiplex peripheral blood in 200+ ILD pts Differences in IL-17 RD-ILD>IPF> IPAF Higher IL-13 strongly asso w/ non-progression of ILD in RD-ILD, IPF & IPAF OR 0.4 Almost surprising considering known profibrotic role of IL-13 🧐 #ACR22 @Rheumnow
Early TNFi use and cardiovascular events in AS Abstract #0415 #ACR22 @RheumNow 📍17.6k patients, 91% male, 80% white 📍TNFi initiators were younger with lower prev. of HTN and DM 📍TNFi was associated with higher risk of incident CVD, CVA, and MACE
Broder et al. HCQ alone vs steroid alone as maintenance in ESKD due to SLE. HCQ less cardiac events, less infection. @RheumNow #ACR22 Abstr#0539
🧨Late breaking abstract🧨 #ACR22 @RheumNow #ACRbest Identifying fetal myocardial targets in congenital heart block (CHB) Abstract #L13 🫀maternal serum underwent mass spec. that identified Ab to 4 protein targets that predicted CHB including anti-ATP1A1 as early as 7w

RA-ILD: an update

Interstitial lung disease (ILD) remains a leading cause of mortality in rheumatoid arthritis (RA). Estimates of involvement of ILD in RA remain relatively imprecise (estimated prevalence 5-20%), though this partly reflects the wide spectrum of ILD and differing ascertainment.

Read Article
Among ANCA-vasculitis hospitalizations, A Fib found to be most common CV condition. Females had fewer CV complications, lower in-hospital mortality & shorter length of stay compared to males. Abs 0434 #ACR22
EULAR19.abstract.jpg (keep)

ACR Best Abstracts - Day 1

Nov 12, 2022

The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).


Read Article
Liew @rheum_cat et al. No evidence of cardioprotective effect of early initiation of TNFi in AxSpA. In fact seemed to be associated higher risk! CVD (HR 1.17), stroke (HR 1.24), and MACE (HR 1.22) @rheumnow #ACR22 Abstr#0415

ACR22 Will Present New Recommendations for Integrative Approach to RA Treatment

Nov 08, 2022

On Sunday Nov. 13, 2022, at ACR Convergence 2022 meeting, the ACR will present a new guideline for Exercise, Rehabilitation, Diet and Additional Integrative Interventions for Rheumatoid Arthritis. This is the first

Read Article
Chest CT Airway Dz compared betw GPA (n26) & relapsing polychondritis (n19). Subglottic involvement favors GPA (OR 28.6) & Extensive airway Dz favor of RP (GP OR 0.02). Lesser RP assoc w/ Posterior tracheal sparing & tracheal calcifications.
Hyperuricemia is assoc w/ adverse CV events in cardiac pts. ALL-HEART study Rx 5721 ischemic heart pts (no gout) w/ usual care of allopurinol. After 4·8 yrs F/U, there was no difference in cardiac outcomes. No allopurinol benefit in IHD
Anakinra in Pericarditis: A Systematic Review (comprehensive, full read) -Options include steroids, colchicine, NSAIDs, pleuropericardial window, IL-1 inhibitors. ANAKINRA - 11 studies, 259 pts, all showing significant rapid resolution.
Tawanese claims analysis of 10,857 RA pts shows lower CVA rates when taking Celebrex (5.95% vs 9.72% not taking) or Etoricoxib (2.69% vs 8.51% not taking). Both Celebrex/Etoricoxib significantly reduced stroke risk p < 0.001

Anakinra in Pericarditis: A Systematic Review (comprehensive, full read) -Options include steroids, colchicine, NSAIDs, pleuropericardial window, IL-1 inhibitors. ANAKINRA - 11 studies, 259 pts, all showing significant rapid resolution.


Predicting Cardiovascular Events in SLE

Oct 13, 2022

A study from the Georgia Lupus Registry shows that systemic lupus erythematosus patients are at greatest risk for cardiovascular disease events between years 2 and 11 after diagnosis and higher in Black people or those with a discoid rash.

Read Article

No Special Heart Risk With JAK Inhibitors, Study Finds

MedPage Today
Oct 11, 2022

Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis experienced similar cardiovascular outcomes as those using the tumor necrosis factor (TNF) blocker adalimumab (Humira), analysis of French national registry data indicated.

Read Article

Rheumatoid Arthritis Patients Need to Quit Smoking ASAP

Oct 04, 2022

While it is known that smoking ups the risk of developing RA, its effect on outcomes in those with established rheumatoid arthritis (RA) is less known.  A report from an early arthritis registry shows that current smoking increases disease activity and lowers health-related quality of life.

Read Article

NSAIDs Linked to Heart Failure in Diabetes Patients

Sep 27, 2022

Short-term use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with a first-time hospitalisation for heart failure in patients with type 2 diabetes, according to research presented at ESC Congress 2022.

Read Article
RheumNow Podcast square

Heavy Metal Rheumatology (9.23.2022)

Sep 23, 2022

Below are this week’s highlights from RheumNow, as discussed by Dr. Jack Cush. Thanks to all of you for your kind comments and great reviews of our weekly podcast. Please let us know how we can improve by emailing me or recording your suggestion using the "Ask Cush Anything" link on our website

Read Article
antibody (Keep)

Clinical Profiles Seen with NXP-2 Antibodies

Sep 20, 2022

A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer.

Read Article
cardiac2.jpg (keep)

Gout Comes With Increased Heart Risk

MedPage Today
Sep 13, 2022

Incidence of acute coronary syndrome (ACS) was significantly higher among gout patients than in the general Swedish population, researchers found, even when data were adjusted for common comorbidities.

First-time ACS was diagnosed at a rate of 9.1 per 1,000 person-years in a cohort of

Read Article